Hypertonic Citrate Solution Protocol Associated with Longer Filter Lifetime in Critically Ill Patients Requiring Continuous Kidney Replacement Therapy
Blood Purification · 2025
DOI: 10.1159/000546579 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Blood Purification, 2025. Verfasst von Anyarin Wannakittirat und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Faculty of Medicine, Naresuan University Hospital, Phitsanulok, Thailand. Hauptthemen laut MEDLINE: Continuous Renal Replacement Therapy, Citric Acid, Anticoagulants. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Introduction
Regional citrate anticoagulation (RCA) serves as the first line of anticoagulants in continuous kidney replacement therapy (CKRT). Premature circuit clotting is associated with increased workload, costs, and adverse patient outcomes. Current evidence shows limited studies on the relationship between RCA protocols and circuit clotting in RCA CKRT. The study aimed to investigate the factors influencing filter lifetime that lead to premature circuit clotting, including citrate formulas employed during RCA in CKRT.
Methods
This retrospective cohort study was conducted at a single center and included patients receiving CKRT from February 2023 to September 2023. The primary outcome was the identification of factors associated premature circuit clotting. Secondary outcomes included circuit ionized calcium levels, citrate doses, blood transfusions, citrate formulations, and other variables that may impact filter clotting.
Results
A total of 199 filters from 97 patients were analyzed in this study. After exclusion of circuit termination due to non-clotting event, 38 filters experienced premature circuit clotting (lifetime ≤72 h), while 70 filters clotted after 72 h. The baseline characteristics and clinical outcomes were well balanced between the groups. In the multivariable analysis, only isotonic citrate formulations (RR 2.45, 95% CI: 1.17–5.14, p = 0.018) and corrected citrate doses (RR 0.48, 95% CI: 0.27–0.87, p = 0.016) exhibited statistically significant associations with filter premature clotting.
Conclusion
Different RCA prescriptions may affect filter lifetime and circuit integrity. Notably, the hypertonic RCA protocol was associated with a significantly longer filter lifetime compared to the isotonic RCA protocol. However, additional data from rigorously constructed randomized controlled trials are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, Faculty of Medicine, Naresuan University Hospital, Phitsanulok, Thailand.
- Excellence Center for Critical Care Nephrology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
- Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Center of Excellence for Critical Care Nephrology, Chulalongkorn University, Bangkok, Thailand.
- Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Academy of Science, Royal Society of Thailand, Bangkok, Thailand.
Zitieren
APA
Wannakittirat, A., Yimsangyad, K., Lumlertgul, N., Peerapornratana, S., & Srisawat, N. (2025). Hypertonic Citrate Solution Protocol Associated with Longer Filter Lifetime in Critically Ill Patients Requiring Continuous Kidney Replacement Therapy. Blood Purification. https://doi.org/10.1159/000546579
Vancouver
Wannakittirat A, Yimsangyad K, Lumlertgul N, Peerapornratana S, Srisawat N. Hypertonic Citrate Solution Protocol Associated with Longer Filter Lifetime in Critically Ill Patients Requiring Continuous Kidney Replacement Therapy. Blood Purification. 2025. doi:10.1159/000546579
BibTeX
@article{Wannakittirat2025,
author = {Wannakittirat, Anyarin and Yimsangyad, Khanittha and Lumlertgul, Nuttha and Peerapornratana, Sadudee and Srisawat, Nattachai},
title = {Hypertonic Citrate Solution Protocol Associated with Longer Filter Lifetime in Critically Ill Patients Requiring Continuous Kidney Replacement Therapy},
journal = {Blood Purification},
year = {2025},
doi = {10.1159/000546579}
}
EUVIMED